logo
Plus   Neg
Share
Email

Helsinn, MEI Pharma Discontinue Phase 3 Study With Pracinostat - Quick Facts

Swiss pharma company Helsinn Group and MEI Pharma, Inc. (MEIP) announced Thursday that they have decided to discontinue the recruitment of patients and end the Phase 3 Study with Pracinostat in Acute Myeloid Leukemia (AML) following an interim analysis.

The interim futility analysis demonstrated that it was unlikely to meet the primary endpoint of overall survival compared to the control group.

The decision was based on a lack of efficacy and not on safety concerns. Pending further evaluation, patients currently enrolled in other pracinostat studies will continue treatment.

The interim analysis was conducted for the ongoing Phase 3 study of pracinostat in combination with azacitidine in patients with AML who are unfit to receive standard intensive chemotherapy, undertaken by the study Independent Data Monitoring Committee (IDMC).

AML is a disorder of the blood and bone marrow caused by the uncontrolled proliferation of an abnormal hematopoietic cell of myeloid lineage. This results in a high circulating number of immature blood cells and replacement of normal bone marrow by malignant cells.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter. The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in...
RELATED NEWS
Follow RTT